State Street SPDR S&P Biotech ETF
474 hedge funds and large institutions have $6.3B invested in State Street SPDR S&P Biotech ETF in 2019 Q4 according to their latest regulatory filings, with 110 funds opening new positions, 122 increasing their positions, 157 reducing their positions, and 35 closing their positions.
214% more first-time investments, than exits
New positions opened: 110 | Existing positions closed: 35
20% more funds holding in top 10
Funds holding in top 10: 10 → 12 (+2)
17% more funds holding
Funds holding: 406 → 474 (+68)
16% more capital invested
Capital invested by funds: $5.44B → $6.3B (+$856M)
7.48% less ownership
Funds ownership: 148.18% → 140.7% (-7.5%)
22% less repeat investments, than reductions
Existing positions increased: 122 | Existing positions reduced: 157
72% less call options, than puts
Call options by funds: $882M | Put options by funds: $3.12B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$413M |
| 2 |
Goldman Sachs
New York
|
+$334M |
| 3 |
N
Natixis
Paris,
France
|
+$170M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$111M |
| 5 |
Barclays
London,
United Kingdom
|
+$71.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$909M |
| 2 |
JP Morgan Chase
New York
|
-$564M |
| 3 |
Citigroup
New York
|
-$168M |
| 4 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$75.6M |
| 5 |
DA
Duality Advisers
Miami,
Florida
|
-$67.2M |
XBI Hedge Fund Activity: Q4 2019 in Review
474 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q4 2019, worth a combined $6.3B — up 16% from $5.44B a quarter earlier.
Buyers outnumbered sellers: 110 funds opened new XBI positions and 35 closed out — a net gain of 75 holders — while 122 added to existing stakes and 157 trimmed.
The largest buyer was Bank of Nova Scotia, adding an estimated $413M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $909M.
- 474 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q4 2019, up from 406 in Q3 2019.
- Funds reported $6.3B of State Street SPDR S&P Biotech ETF stock for Q4 2019, up 16% quarter-over-quarter.
- 110 funds opened new State Street SPDR S&P Biotech ETF positions in Q4 2019 and 35 closed out, a net change of +75 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q4 2019 was Bank of Nova Scotia, an estimated $413M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q4 2019 was BNP Paribas Financial Markets, an estimated $909M sold.
Based on aggregated 13F filings for Q4 2019.